학술논문
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Document Type
article
Author
Mamadou Samb Yade; Baba Dièye; Romain Coppée; Aminata Mbaye; Mamadou Alpha Diallo; Khadim Diongue; Justine Bailly; Atikatou Mama; Awa Fall; Alphonse Birane Thiaw; Ibrahima Mbaye Ndiaye; Tolla Ndiaye; Amy Gaye; Abdoulaye Tine; Younouss Diédhiou; Amadou Mactar Mbaye; Cécile Doderer-Lang; Mamane Nassirou Garba; Amy Kristine Bei; Didier Ménard; Daouda Ndiaye
Source
Malaria Journal, Vol 22, Iss 1, Pp 1-7 (2023)
Subject
Language
English
ISSN
1475-2875
Abstract
Abstract Background Malaria control is highly dependent on the effectiveness of artemisinin-based combination therapy (ACT), the current frontline malaria curative treatment. Unfortunately, the emergence and spread of parasites resistant to artemisinin (ART) derivatives in Southeast Asia and South America, and more recently in Rwanda and Uganda (East Africa), compromise their long-term use in sub-Saharan Africa, where most malaria deaths occur. Methods Here, ex vivo susceptibility to dihydroartemisinin (DHA) was evaluated from 38 Plasmodium falciparum isolates collected in 2017 in Thiès (Senegal) expressed in the Ring-stage Survival Assay (RSA). Both major and minor variants were explored in the three conserved-encoding domains of the pfkelch13 gene, the main determinant of ART resistance using a targeted-amplicon deep sequencing (TADS) approach. Results All samples tested in the ex vivo RSA were found to be susceptible to DHA (parasite survival rate